Celularity Inc
No enriched coverage for $CELU in the last 7 days.
No SEC Form 4 filings for $CELU in the last 30 days.
See all $CELU insider activity →Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
Celularity (CELU) partners with MuseCell Innovations to manufacture Dezawa MuseCells in the U.S. The deal could generate $300M in purchases over five years. Celularity's stock is up 64.70% to $1.48.
Summit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.
Recent CELU coverage spans corporate actions, financial news and regulation.
Collaboration could generate >$300 M in purchases over five years, bullish for CELU.
The deal expands Celularity's manufacturing footprint and revenue pipeline.
Compliance issue creates short‑term volatility but limited long‑term impact.
Potential delisting risk if filings are not submitted, could pressure share price.
The immediate CCO departure is a company-specific operational risk and may prompt near-term changes in go-to-market, partnerships, or sales leadership.
alphai scores every news story that mentions CELU with an AI model for sentiment and relevance, and aggregates insider trades from Celularity Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
3 min readCelularity (CELU) partners with MuseCell Innovations to manufacture Dezawa MuseCells in the U.S. The deal could generate $300M in purchases over five years. Celularity's stock is up 64.70% to $1.48.
2 min readSummit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.
3 min readCelularity Inc. (CELU) received a Nasdaq notice for late quarterly filings, failing to submit reports for Q1 and Q2 2026. The company has until September 4 to submit a compliance plan. Trading continues on Nasdaq under 'CELU'. Celularity is working to file the reports promptly.
1 min readCelularity Inc (CELU) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 5, 2026, Celularity Inc. (the “Company”) terminated the employment of Rick Gonzalez, the Company’s Chief Commerc
2 min readCelularity Inc (CELU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 LOAN agreement This Loan Agreement, dated as of June 29, 2026 (“ Agreement ”), is among Celularity Inc., a Delaware corporation (the “ Borrower ”), and Philip & Daniele Barach Family Trust (the “ Lender ” and, together with the Borrower,
3 min readCelularity Inc (CELU) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001752828 0001752828 2026-06-19 2026-06-19 0001752828 CELU:ClassCommonStock0.0001ParValuePerShareMember 2026-06-19 2026-06-19 0001752828 CELU:WarrantsEachExercisableForOnetenthOfOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2026-06-19 2026-06-19 iso4217:US
3 min readThis Simply Wall St analysis provides a detailed stock report for Celularity (Nasdaq:CELU), a regenerative and cellular medicines company, as of May 2026. The report covers valuation, future growth, past performance, financial health, dividend, management, and ownership, indicating a small market cap and negative shareholder equity. It also highlights recent news including funding, delayed filings, earnings reports, and clinical trial updates for its various product candidates.
3 min readThis article highlights several stocks to watch on Friday after hours, including Cantaloupe, Inc. (CTLP), CELU, and ULH. It notes that the stock market closed modestly higher on Friday, starting May on an optimistic note due to retreating oil prices and strong corporate earnings. The S&P 500 rose by 0.3%.
2 min readNexgel Inc. and Celularity have executed Amendment No. 1 to their license agreement on April 17, 2026. This announcement by Reuters was published on April 21, 2026, at 06:27 pm EDT. The article also provides a company profile for Nexgel, Inc., detailing its focus on hydrogel products for various applications and its financial outlook with analyst consensus.
2 min read
